# Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

> **NCT01918865** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 92 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Obese

## Interventions

- **DRUG:** ISIS-PTP1BRx
- **DRUG:** Placebo
- **DRUG:** daily OAD (metformin and/or sulfonylurea)

## Key facts

- **NCT ID:** NCT01918865
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-10
- **Final completion:** 2015-02
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2015-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01918865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01918865, "Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01918865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*